trending Market Intelligence /marketintelligence/en/news-insights/trending/c4gTa9tCZyzrb2AGe7reTQ2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

DBV Technologies' peanut allergy therapy sustains benefit over long term

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

DBV Technologies' peanut allergy therapy sustains benefit over long term

DBV Technologies SA said its peanut allergy therapy continued to benefit children over a longer term.

The news helped boost the company's stock price by 17.88% to $13.25 per share in pre-market trading Jan. 9.

Of the 141 children who received Viaskin Peanut, 75.9% had increased their tolerance to peanut protein after three years of treatment, including 51.8% of patients that could tolerate at least 1,000 milligrams of peanut protein. Most children with peanut allergies react to 300 milligrams of peanut protein or less, with some having a reaction to even 1 milligram of the protein.

The French company was reporting results from a phase 3 clinical trial called People, which built on the results of the late-stage Pepites study by following up on patients — aged 4 to 11 years — over a longer period of time. The company's exploratory data analysis also suggested that Viaskin Peanut's effects could persist even after a period without treatment.

DBV's medicine was also found to be safe, with the most common adverse events categorized as mild to moderate skin reactions.

Viaskin Peanut is a patch applied to the back, providing desensitization to the peanut allergen. It holds the U.S. Food and Drug Administration's breakthrough and fast-track designations and is under review by the regulator with expectations that it could reach the market in the second half of 2020.

The therapy would compete with Aimmune Therapeutics Inc.'s AR101, which is also under review in the U.S., with a decision expected later this month.